Related references
Note: Only part of the references are listed.Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis
Gerd R. Burmester et al.
RHEUMATOLOGY (2016)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Karel Pavelka et al.
JOURNAL OF RHEUMATOLOGY (2015)
Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials
Young Ho Lee et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Pharmacokinetic-Pharmacodynamic Modeling of Fostamatinib Efficacy on ACR20 to Support Dose Selection in Patients With Rheumatoid Arthritis (RA)
John Maringwa et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds
Vibeke Strand et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2014)
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets
Daniel E. Furst et al.
RHEUMATOLOGY (2014)
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
Lisa G. M. van Baarsen et al.
ARTHRITIS RESEARCH & THERAPY (2014)
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis
David A. Martin et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway
Saba Alzabin et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization
Marije I. Koenders et al.
ARTHRITIS AND RHEUMATISM (2012)
Interleukin-23: as a drug target for autoimmune inflammatory diseases
Chunlei Tang et al.
IMMUNOLOGY (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
Devesh Mewar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients With Rheumatoid Arthritis A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
M. C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2010)
Role of Th17 Cells in Human Autoimmune Arthritis
Jan Leipe et al.
ARTHRITIS AND RHEUMATISM (2010)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
Steven S. Storage et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2010)
Structural basis of receptor sharing by interleukin 17 cytokines
Lauren K. Ely et al.
NATURE IMMUNOLOGY (2009)
IL-17 as a future therapeutic target for rheumatoid arthritis
Wim B. van den Berg et al.
NATURE REVIEWS RHEUMATOLOGY (2009)
Mechanisms of Disease: Interleukin-17 and Type 17 Helper T Cells.
Pierre Miossec et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis?
Erik Lubberts
CYTOKINE (2008)
Interleukin-17 family and IL-17 receptors
TA Moseley et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo
LP Cai et al.
CYTOKINE (2001)
Are T cells in rheumatoid synovium aggressors or bystanders?
P Miossec
CURRENT OPINION IN RHEUMATOLOGY (2000)
Share Paper
